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Abstract  
Purpose: To identify the period prevalence of hormonal contraceptive (HC) use and 
characterise the perceived side effects associated with the menstrual cycle and HC use. 
Methods: 430 elite female athletes completed a questionnaire to assess; the period prevalence 
of HC use, the reasons for initiation and discontinuation of HCs and the side effects experienced 
by HC and non-HC users. Descriptive statistics, between-group comparisons and associations 
between categorical variables were calculated. Results: 49.5% of athletes were currently using 
HCs and 69.8% had used HCs at some point. Combined oral contraceptives were most 
commonly used (68.1%), with 30.0% using progestin-only contraceptives (implant = 13.1%; 
injection = 3.7%; intrauterine system = 2.8%). Perceived negative side effects were more 
common with progestin-only HC use (39.1%) compared to combined HC use (17.8%; P = 
0.001) and were most prevalent in implant users (53.6%; P = 0.004). HC users reported 
perceived positive side effects relating to the ability to predict and/or manipulate the timing, 
frequency and amount of menstrual bleeding. Non-HC users had a menstrual cycle length of 
29 ± 5 d and 77.4% reported negative side effects during their menstrual cycle, primarily during 
days 1-2 of menstruation (81.6%). Conclusions: Approximately half of elite athletes used HCs 
and progestin-only contraceptive users reported greater incidences of negative side effects, 
especially with the implant. Due to the high inter-individual variability in reported side effects, 
athletes and practitioners should maintain an open dialogue to pursue the best interests of the 
athlete. 
Keywords: menstrual cycle, hormonal contraceptives, side-effects, female athletes, prevalence 
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Introduction 
Alterations to the female reproductive-axis influence health and athletic performance.1–
3 Between menarche and the menopause, non-hormonal contraceptive users typically have a 
monthly menstrual cycle, with a cyclical rise and fall in sex hormone concentrations.4 Primary 
dysmenorrhea, which is characterised by painful menstruation, nausea, headaches, fatigue and 
diarrhoea,5 is experienced by 60-91% of non-hormonal contraceptive users6 and may affect 
athletic performance.7 In a recent study, 51% of athletes (n = 90) perceived that the menstrual 
cycle affected their training and performance.8 Despite this, little is known about menstrual 
cycle related side effects, when they occur and how training and performance may be 
influenced. 
Hormonal contraceptives (HCs) are exogenous steroid hormones that inhibit ovulation 
and result in consistently low endogenous sex hormone concentrations, which can be used to 
treat dysmenorrhea.9,10 There are different delivery methods for HCs including the oral 
contraceptive (OC), implant, injection, transdermal patch, vaginal ring and intra-uterine system 
(IUS). In the UK, a hormone releasing coil is typically referred to as an IUS, whereas a copper-
based, non-hormone releasing coil is referred to as an intra-uterine device (IUD) and, as such, 
would not be considered a type of HC. Hormonal contraceptives can also be classified by type; 
combined, with an oestrogenic and progestin component, or progestin-only. The type and 
concentration of oestrogen and progestin varies between different preparations of contraceptive, 
and may influence the physiological response.11–13 
In a large-scale epidemiological study of >194,000 women, Cea-Soirano et al.14 
reported that 30% of 16-49 year olds in the UK used HCs: combined OCs (16.2%), progestin-
only OCs (5.6%), IUSs (4.2%), injections (2.4%), implants (1.5%), transdermal contraceptive 
patches (0.1%), with 4.5% using non-hormonal copper-based coils (IUDs). The prevalence of 
HC use in athletes has been poorly defined by previous research. In elite Norwegian athletes, 
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OC use was 40.2%, which was significantly higher than a control population (27%),15 while 
46% of Swedish football, volleyball and basketball athletes used OCs.16 Other studies have 
reported low OC use in athletes (~14%),17,18 although this may be due to the inclusion of non-
elite athletes, who may be more analogous to the general population. Previous research in elite 
athletes has only reported OC use and has not considered other delivery methods of HCs or 
detailed the preparations used by participants, which influence endogenous hormone 
concentrations and other physiological processes.11–13 No study has identified the reasons why 
elite athletes initiate or discontinue HC use, or the perceived side effects. 
Elite female athletes are required to train and compete whilst having to manage changes 
in sex hormone concentration and their subsequent side effects. The current lack of 
understanding of these side effects is a barrier to implementing strategies to support athletes 
and promote optimal health and performance. The aim of this study was to identify (1) the 
period prevalence of HC use, (2) the reasons for initiation and discontinuation of HCs and (3) 
the side effects experienced by HC users and non-users in an elite athletic population. 
Materials and methods 
Participants 
Between 2015-2016, elite female athletes were recruited through National Governing 
Bodies, coaching and support staff, or by approaching the athletes directly. Athletes had to 
be >18 y and competing at a national, international or professional (full-time and salaried) level. 
A paper-based questionnaire was used in order to minimise the possibility that the 
questionnaire could be completed by the non-targeted population.19 A total of 476 athletes 
completed the questionnaire, with 430 responses included in the final analysis (Figure 1). 
Athletes were recruited from 24 sports with 361 competing at an international/professional 
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level and 69 competing nationally. All participants provided written informed consent and the 
study was approved by the Nottingham Trent University non-invasive ethics committee.  
Questionnaire 
Data were collected using a paper-based questionnaire that was specifically designed 
for the purposes of the study. All data were provided by the athletes and reflect their perceptions 
and experiences. Participants recorded demographic information including age, height, weight, 
age of menarche, sport, competitive level, length of time competing at this level and weekly 
training frequency and duration (Table 1 and Figure 1). Current HC users and non-HC users 
were directed to complete different sections of the questionnaire. Non-HC users were asked 
whether they used a IUD, their typical menstrual cycle duration and variability in length. 
Participants were asked to state whether they experienced pain or other symptoms during the 
menstrual cycle and whether they avoided exercise/training at any point of their cycle. Where 
applicable, participants were asked, in an open-ended question, to state the symptoms/reasons 
and time points when these occurred. Current HC-users were asked to provide the delivery 
method, preparation and duration of use for their current HC. Participants were asked whether 
they had discussed their HC with their coach/team doctor and whether the coach/team doctor 
was involved in the decision to use this type of HC. Participants were asked why they had 
chosen this method of HC, whether they considered possible side effects prior to commencing 
HC use, and whether they have experienced any negative or positive side effects. Where 
applicable, participants were asked to provide supporting information in an open-ended 
question. Non-HC users and HC users were then asked to detail previous HC use, including 
the delivery method, preparation, duration of use and reason for discontinuation for all previous 
HCs used.  
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Data analysis 
Data were analysed using Microsoft Excel and IBM SPSS (v. 23.0). To prevent 
duplicate data, the database was searched for non-unique date of births and identical values 
were visually checked to assess whether the respondents were different. Athletes were 
categorised by competitive level (national or international/professional) to conduct a stratified 
analysis. For open-ended questions, a content analysis was conducted independently by two 
researchers (DM, KES) to categorise responses, whereby a frequency analysis was performed, 
which was checked for consistency. Differences between the researchers were resolved by 
discussion until a consensus was reached. Direct verbatim quotes were used to inform 
interpretation in some instances. Assumptions of normality were checked using the Shapiro-
Wilk test and between group differences were examined using independent samples t-tests, 
Mann-Whitney U tests and Kruskal Wallis H tests. Pearson’s chi-squared analyses were used 
to examine the relationships between categorical variables, with Fishers exact tests used where 
<80% of expected cell counts were >5.20 Data are represented as mean ± 1SD, frequencies and 
percentages and statistical significance was set at p ≤ 0.05.  
Results 
Three hundred (69.8%) athletes reported using HCs at some point, with 49.5% of 
athletes currently using HCs and 50.5% not currently using any form of HC (Fig 1). Hormonal 
contraceptive users had a lower age of menarche (p = 0.010) and length of time competing at 
current level (p = 0.048) compared to non-HC users (participant characteristics in Table 1). 
Competitive level did not influence the prevalence of HC use (p > 0.05). 
Menstrual cycle (non -hormonal contraceptive users) 
Three athletes described themselves as amenorrheic, although the questionnaire did not 
specifically ask this question. Thirty-four athletes did not report their menstrual cycle length or 
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did not provide enough information to interpret a response. Mean cycle length for the remaining 
athletes was 29 ± 5 d. Eight athletes reported a mean menstrual cycle duration of greater than 
35 days and three athletes reported a mean menstrual cycle duration of less than 21 days. One-
hundred and four (48.6%) athletes stated that their menstrual cycle was non-variable in length, 
while 110 (51.4%) athletes reported their cycle length to be variable with a mean variation of 
9 ± 9 d. Copper IUDs were used by 2 participants (0.9%); with a mean menstrual cycle length 
of 28 ± 4 d. Menstrual cycle-related negative symptoms were reported by 168 athletes (77.4%) 
and categorical frequencies are presented in Table 2. Symptoms were experienced in the week 
prior to menstruation (25.0%), during days 1 and 2 of menstruation (81.6%) and between day 
3 and the end of menstruation (28.9%). Nine athletes (4.1%) reported that they had to refrain 
from exercise at certain points of their menstrual cycle. Reasons included pain (n = 4), sickness 
(n = 2), or other reasons (n = 3), such as “Literally struggle to get out of bed so training is out 
of the question” or “at the beginning of the menstrual cycle I avoid to do tough session [sic]”. 
Four athletes reported that they didn’t refrain from exercise, although they provided additional 
comments stating “No – but only because I can’t”, “but struggle with contact [rugby]”, “but I 
get back cramps 1 week before when running” and “I don’t avoid it but I do sometimes have 
to delay things until cramps calm down”. One athlete stated that “If anything I have to increase 
it [exercise]. Helps to pass quicker by maybe a day and helps the pain”. 
Hormonal contraceptive use 
Combined HCs comprised 68.5% of HC use, with 30.0% using progestin-only and 1.9% 
using an unspecified type of OC. There was no difference in length of current HC use between 
combined (4.6 ± 3.7 y) and progestin-only HC users (3.9 ± 4.4 y; p = 0.193), or between 
different delivery methods (p = 0.649). Oral contraceptives were the most widely used (78.4%), 
followed by the implant (13.1%), injection (3.8%), IUS (2.8%) and vaginal ring (0.5%), with 
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one participant using a combination of the implant and OC. All combined OCs were 
monophasic and contained ethinyl oestradiol (EO) as the oestrogenic component in varying 
doses: 20 µg (n = 4, 2.8%), 30 µg (n = 116, 80.0%), 35 µg (n = 19, 13.1%). Six participants (n 
= 4.1%) used combined preparations but did not specify the oestrogenic dose. Twelve different 
progestins were used in various doses, with Levonorgestrel accounting for 51.4% of progestin 
use.  
The most common reason athletes chose their specific type/delivery method was ease 
of use (18.8%), and the most common side effects considered prior to HC use were weight gain 
(33%) and mood changes/swings (12.7%). The side effects experienced by HC-users are shown 
in Table 3. Negative side effects were significantly more common with progestin-only HCs 
(39.1%) compared to combined HCs (17.8%; p = 0.001) and were significantly more common 
in the implant (53.6%) compared to other delivery methods (p = 0.004; Table 4). Type and 
delivery method of HC did not affect the prevalence of reported positive effects (p > 0.05). HC 
users were significantly more likely to report positive effects of HCs than negative effects (p < 
0.05).  
International/professional athletes were significantly more likely to discuss HC use 
with their coach/team doctor (25%) compared to national level athletes (0%; p < 0.001). 
Competitive level did not influence coach/team doctor involvement in the decision to initiate 
HC use (p = 0.070), although this did occur for 7.6% of international/professional athletes and 
no national level athletes. The coach/team doctor was involved in the decision to use HCs for 
14 (6.6%) athletes, of which 12 used OCs and 2 used an implant. Ultra-low dose EO (20 µg) 
OCs accounted for 25% of OC use in this group, in comparison to 2.7% of overall OC use, 
which was a significant effect (p = 0.010). Where the coach/team doctor was involved in the 
decision, athletes stated that they were prescribed these HCs for contrasting reasons including; 
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‘Higher level of oestrogen”, “Apparently lowest oestrogen”, “Low hormones” and “In attempt 
to reduce monthly fluctuations in my performance and fatigue”. 
In total, 87 (40.1%) non-HC users had previously used some form of HC, with 64 
(30.0%) current HC users previously using a different HC. There were 218 incidences of 
previous HC use, as some athletes had used 2 (n = 49), 3 (n = 13), 4 (n = 4) and 5 (n = 1) 
previous types of HC. Combined OCs accounted for 78.4% of previous use, with progestin-
only OCs (7.8%), implant (7.8%), injection (6.0%) and IUS (1.8%) also used. The reasons 
provided for discontinuation of previous HCs are presented in Table 5. Mean duration of 
previous HC use was 2.2 ± 2.3 y, with no difference between types (p = 0.360) or delivery 
methods (p = 0.733). 
Discussion 
This novel study has shown that there is an approximately even prevalence of HC use 
and non-HC use in elite female athletes. The majority of female athletes have used HCs at some 
point in their sporting career. These results highlight the importance of understanding the 
effects of the menstrual cycle and HC use in elite sportswomen. This is the first study to detail 
the symptoms experienced by athletes during the menstrual cycle and with HC use, and these 
data can be used to inform the decisions of athletes, practitioners and researchers. 
The prevalence of HC use in elite athletes (49.5%) is higher than recent data for the 
general population of reproductive age in the UK (30.0%)14 and USA (27.6%).21 Sixty-nine 
percent of HCs used were combined OCs, which is also higher than in the general population 
where OCs account for 54.0% of HC use.14 Schaumberg et al.22 , showed that competitive (state, 
national and international) athletes rated sport competition and sport training as more important 
factors in menstrual manipulation with OCs, compared to sub-elite and recreationally active 
individuals. Furthermore, 43.5% of OC-using competitive athletes planned to manipulate 
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menstruation often, which was greater than sub-elite (22.5%) and recreationally active women 
(15.8%). In the current study, nearly a third of combined OC users perceived the ability to 
predict or manipulate menstruation, thereby avoiding menstruation during training or 
competition, as a positive effect, which may explain the differences in OC use between elite 
athletes and the general population. Progestin-only HCs accounted for 30.0% of use, with the 
implant (13.1%) and progestin-only OC (10.3%) being the most widely used. Almost 40% of 
progestin-only HC users perceived the cessation of, or less frequent bleeding, as a positive 
consequence of this type of HC. Previous research has documented the prevalence of OC use 
in athletes.15,16 however the current study has provided a more comprehensive overview of HC 
use by including all types and delivery methods of HCs, in addition to the preparations, which 
enables the quantification of steroid hormone content and concentrations. Twelve different 
progestins were used in varying concentrations, with EO being the oestrogenic component in 
all combined preparations. Four HC users were prescribed ultra-low dose (20 µg EO) OCs; 
with three cases involving the coach/team doctor in the decision to use this preparation, all of 
which were from different sports. Ultra-low dose OCs are associated with reduced headaches, 
nausea and breast tenderness compared to higher dose EO formulations23 and can reduce the 
symptoms of dysmenorrhea24, so may have been prescribed to reduce these symptoms whilst 
maintaining the benefits of improved cycle control. These data are representative of a UK based 
population and further studies are required to expand this knowledge to other countries where 
the use of other formulations, such as extended cycle OCs, are more prevalent.25 
Combined HCs were better tolerated than progestin-only HCs; with 17.8% of 
combined-type users reporting negative side effects in comparison to 39.1% of progestin-only 
HC users. In particular, the implant had a significantly higher incidence of reported negative 
symptoms compared to other delivery methods of HCs (Table 4). One third of athletes 
considered weight gain as potential side effect prior to HC initiation, although only 7.5% 
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reported increased weight which is lower than in the general population (34%).26 Hormonal 
contraceptive users were more likely to report positive than negative side effects, which may 
have implications for athletes considering HC use in the future. Nineteen negative and 23 
positive categories of side effects were identified, emphasising the individuality of responses 
and that athletes should be considered on a case by case basis. The most prevalent, positive 
side effects reported were the ability to predict/change menstruation (n = 45), having regular 
periods (n = 27) and cessation of/less frequent bleeding (n = 26), showing that changes to the 
timing, frequency and amount of bleeding with HC use were well-received. It should be noted 
that athletes were asked to state the non-contraceptive benefits of HC use, therefore the primary 
benefit and reason of HC use may have been for contraception. 
Sixty-four (30.0%) HC users previously used a different form of HC and 87 (40.1%) 
non-HC users had previously used a form of HC. The most common reasons provided for 
discontinuation of HCs were: they were no longer needed (19.9%), they altered mood (19.2%), 
resulted in weight gain (18.5%) and caused headaches/migraines (11.9%). It is important to 
note that 46 separate reasons were provided for discontinuation of HCs, emphasising the high 
inter-individual response. This further emphasises that sport practitioners should openly 
discuss HC use and side effects with athletes to monitor athletes’ health, well-being and 
performance.   
Negative side effects associated with the menstrual cycle were reported by 77.4% of 
non-HC users, which is similar to the general population.6 Exercise may reduce the occurrence 
and severity of dysmenorrhea,27 although dysmenorrhea is still widespread in elite athletes. 
The most commonly reported side effects were stomach cramps (47.5%), unspecified cramps 
(22.1%), back pain (17.1%) and headaches/migraines (9.7%). Despite having physically 
demanding lifestyles, only 4.2% of athletes stated that they refrained from exercise at certain 
points of their menstrual cycle, which is lower than the general population where dysmenorrhea 
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limits daily activities in 15-29% of women.6 This discrepancy may be caused by internal and 
external pressures to perform,28 meaning that athletes persevere with training whilst 
experiencing severe symptoms, evidenced by responses such as “No, but only because I can’t 
[avoid exercise]”. A recent study in HC users and non-users, showed 51.1% of athletes thought 
their menstrual cycle affected training and performance,8 although the current data indicates 
that this rarely translates into athletes modifying training schedules to accommodate symptoms.  
Twenty-four distinct, negative symptoms were reported by non-HC users (Table 2) and 
approximately half of the athletes reported menstrual cycle length variability with a relatively 
high mean variation of (9 ± 9 d) in these athletes. Although the current questionnaire did not 
ask specifically about amenorrhea, three athletes described themselves as amenorrheic, and we 
recommend that future studies explicitly ask this question in order to not under-represent the 
occurrence of amenorrhea in elite sport. Side effects were mostly experienced during the first 
two days of menstruation (81.6%), however also occurred in the week prior to menstruation 
(25.0%) and between day 3 and the end of menstruation (28.9%). These data emphasise the 
individuality of responses and the importance of athletes monitoring their menstrual cycle and 
associated symptoms. We suggest that athletes and coaches/support staff should maintain an 
open dialogue about the menstrual cycle and encourage flexibility in training schedules, when 
possible, to accommodate the most severe side effects. 
With half of elite athletes using HCs, future research should include HC users and non-
users in order to represent the female athlete population.  Progestin-only contraceptives 
constitute ~30% of HC use in athletes, although we are unaware of any research available to 
identify the effects of these contraceptives on athletic performance and health. Twenty-five 
different preparations of HC were identified in this study, containing different doses of 
oestrogens and progestins, which may have different physiological effects.11–13 Therefore, 
future research should focus on (1) examining differences in responses between HC users and 
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non-users, (2) progestin-only contraceptive users and (3) differences between preparations of 
HC.  
Practical Applications  
Progestin-only contraceptives had a greater incidence of negative side effects and 
physicians may want to consider the increased prevalence of perceived negative side effects 
with these contraceptives. There is a large degree of individuality in the type and severity of 
symptoms experienced during the menstrual cycle and HC use, and in the reasons for initiating 
and discontinuing HC use. It is recommended that athletes and practitioners discuss side effects 
experienced with the menstrual cycle and HC use in order to suit the athletes’ best interests. 
This research also highlights that future research should include HC users and non-users in 
order to represent the female athlete population.  
Conclusions 
Approximately half of elite athletes use some type of HC, with combined OCs most 
commonly used, possibly due to the ability to predict and/or manipulate the timing, frequency 
and amount of menstrual bleeding. A large proportion of sportswomen use progestin-only 
contraceptives with a perceived benefit being that they induce amenorrhea. There is a larger 
inter-individual variability in response to HC use and the menstrual cycle which should be 
considered by athletes and practitioners. 
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Figure 1. The prevalence of type, delivery method and preparation of hormonal contraceptives (HCs) used and the prevalence of non-HC use. 
IUD, Intrauterine device; IUS, Intrauterine system; DNS, dose not specified; OC, oral contraceptive.
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Table 1. Participant characteristics for hormonal contraceptive (HC) users and non-HC users. 
 
Demographic information HC users Non HC users Total 
Age (y) 24.1 ± 4.5 24.3 ± 4.3 24.2 ± 4.4 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 
Weight (kg) 66.2 ± 9.8 66.0 ± 9.3 66.1 ± 9.6 
Body mass index (kg·m2) 23.1 ± 2.6 23.0 ± 2.5 23.1 ± 2.5 
Age at menarche (y) 13.4 ± 1.5 13.8 ± 1.3 13.6 ± 1.4* 
Gynaecological age (y) 10.7 ± 4.6 10.6 ± 4.6 10.6 ± 4.6 
Duration competing at current level (y) 5.0 ± 3.6 5.7 ± 4.1 5.4 ±3.9* 
No. training session per week 8.5 ± 4.5 8.4 ± 4.0 8.5 ± 4.3 
Average training session duration (mins) 92.8 ± 29.8 89.1 ± 27.8 90.9 ± 28.8 
Total weekly training duration (mins) 769.7 ± 440.8 720.3 ± 385.6 744.6 ± 413.9 
* Indicates a significant difference between HC users and non-HC users (p < 0.05) 
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Table 2. Frequency and prevalence of physical and emotional symptoms reported during the 
menstrual cycle for non-hormonal contraceptive users. 
 
 Symptom Frequency Prevalence (%) 
Physical  Stomach cramps/abdominal pain 103 47.5 
 Unspecified cramp 48 22.1 
 Back pain  37 17.1 
 Headache/migraine 21 9.7 
 Bloating 12 5.5 
 Nausea/sickness/vomiting 10 4.6 
 Tiredness/fatigue/lethargy 9 4.1 
 Dizzy/lightheaded/lack of coordination 5 2.3 
 Leg discomfort 4 1.8 
 Unspecified pain 3 1.4 
 Hot flushes/sweating 2 0.9 
 Hunger/increased appetite 2 0.9 
 Sore breasts 2 0.9 
 Bad skin 1 0.5 
 Constipation 1 0.5 
 Heavy bleeding 1 0.5 
 Muscle ache 1 0.5 
 Problems with exercise 1 0.5 
 Sore throat 1 0.5 
 Tight neck 1 0.5 
 Weakness 1 0.5 
Emotional  Mood changes/swings 9 4.1 
 Irritability 1 0.5 
 Flustered 1 0.5 
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Table 3. Prevalence of reported negative and positive side effects for current hormonal contraceptive use. 
 
 Negative effect Frequency Prevalence (%) Positive effect Frequency Prevalence (%) 
Physical Weight gain 16 7.5 Regular period 27 12.7 
 Irregular periods 9 4.2 Cessation of/less frequent periods 26 12.2 
 Poor skin 6 2.8 Reduced bleeding/lighter periods 23 10.8 
 Headaches/migraines 4 1.9 Improved skin 13 6.1 
 Altered cycle length 3 1.4 Reduced period pain 10 4.7 
 Breast issues (bigger/sore) 3 1.4 Reduced cramps (unspecified) 7 3.3 
 Constant/irregular bleeding 3 1.4 Reduced pain (unspecified) 6 2.8 
 Spotting 3 1.4 Reduced headaches/migraine 3 1.4 
 Tiredness/fatigue/lethargy 3 1.4 Increased iron 3 1.4 
 Effect on training/performance 2 0.9 Less ill/sick 3 1.4 
 Nausea/sickness/vomiting 2 0.9 Resumption of cycle from amenorrhea 3 1.4 
 Water retention 2 0.9 Reduced stomach cramps 3 1.4 
 Abnormal liver function 1 0.5 Effect on training/performance 2 0.9 
 Bloating 1 0.5 Reduced bloating 1 0.5 
 Hormone imbalance 1 0.5 Improved bone density 1 0.5 
 Increased appetite 1 0.5 Less faint 1 0.5 
 Stomach pain 1 0.5 Reduced fluctuations in water retention 1 0.5 
 Unspecified pain 1 0.5 Reduced fluctuations in weight 1 0.5 
    Reduced PCOS side effects 1 0.5 
Emotional Mood changes/swings 9 4.2 Improved mood 3 1.4 
Both        Helps PMT 1 0.5 
Practical       Ability to predict/change cycle date 45 21.1 
    Couldn’t forget to take 3 1.4 
PCOS, Polycystic ovarian syndrome; PMT, Pre-menstrual tension. 
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Table 4. Prevalence of reported negative and positive effects of hormonal contraceptive use in current users, separated by type and delivery 
method of hormonal contraceptive 
 
  Type of hormonal contraceptive   Delivery method of hormonal contraceptive 
 Combined 
Progestin
-only 
Total  OC Implant Injection IUS 
Vaginal 
ring 
Total 
Experienced negative symptoms 26 25 51   35 15 2 2 0 54 
Didn’t experience negative symptoms 120 39 159  136 13 6 4 1 214 
Percentage with symptoms (%) 17.8 39.1 24.4*  20.5 53.6 25.0 33.3 0.0 25.2* 
                      
Experienced positive effects 99 42 141  117 18 3 5 1 144 
Didn't experience positive effects 47 22 69  54 10 5 1 0 70 
Percentage with symptoms (%) 67.8 65.3 67.1  68.4 64.3 37.5 83.3 100.0 67.3 
* Indicates a significant effect of type or delivery method (P < 0.05). OC, oral contraceptive; IUS, intrauterine system. 
 
 
D
ow
nl
oa
de
d 
by
 G
ot
eb
or
gs
 U
ni
ve
rs
ite
t o
n 
12
/2
9/
17
, V
ol
um
e 0
, A
rti
cl
e N
um
be
r 0
“Period Prevalence and Perceived Side Effects of Hormonal Contraceptive Use and the Menstrual Cycle in Elite Athletes” 
by Martin D, Sale C, Cooper SB, Elliott-Sale KJ 
International Journal of Sports Physiology and Performance 
© 2017 Human Kinetics, Inc. 
 
Table 5. Reasons, frequency and prevalence for discontinuation of previous hormonal 
contraceptives.  
 
 Reason Frequency Prevalence (%) 
Physical symptoms Weight gain 28 12.8 
 Headaches/migraine 18 8.3 
 More frequent or heavier bleeding 13 6.0 
 Irregular/no bleeding 10 4.6 
 Poor skin 7 3.2 
 Constant bleeding 6 2.8 
 Fatigue/tiredness/lethargy 6 2.8 
 Bone health 5 2.3 
 Impaired training/performance/recovery 5 2.3 
 Nausea/vomiting 4 1.8 
 Resumption/regulation of menses 4 1.8 
 Stomach cramps 3 1.4 
 Stroke and cancer risk 3 1.4 
 Water retention 3 1.4 
 Cramps 2 0.9 
 Hormone imbalance 2 0.9 
 Impaired sleep 2 0.9 
 Low libido 2 0.9 
 Painful periods 2 0.9 
 Bloating 1 0.5 
 Blood pressure 1 0.5 
 Blood side effects [sic] 1 0.5 
 Breast pain 1 0.5 
 Dizziness and blurred vision 1 0.5 
 For oestrogen reasons [sic] 1 0.5 
 Hot flushes 1 0.5 
 Illness 1 0.5 
 Pain during intercourse 1 0.5 
 PMS 1 0.5 
 Removed to assess oestrogen level 1 0.5 
Emotional symptoms Mood 29 13.3 
 Wanting to be “normal” / “natural” 5 2.3 
 Depression 4 1.8 
 Needed a rest/break 3 1.4 
Practical Not sexually active/not needed 30 13.8 
 Forgetting to take pill 16 7.3 
 Doctor/nurse recommendation 11 5.0 
 Didn’t like it 10 4.6 
 Pregnancy 6 2.8 
 New preparation/type 4 1.8 
 Ran out 4 1.8 
 Went abroad/travelling 4 1.8 
 Ineffective 3 1.4 
 Wanted something different/permanent 2 0.9 
 Word of mouth 2 0.9 
 Loss of effect[sic] 1 0.5 
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